{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:39:47Z","timestamp":1790285987850,"version":"4.1.0"},"reference-count":42,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,11]]},"abstract":"<jats:p>Mefloquine was widely prescribed to U.S. military service members until 2009 when use was limited to personnel with contraindications to doxycycline and no contraindications to mefloquine. The need to estimate the occurrence of neuropsychiatric outcomes (NPOs) in service members prescribed mefloquine warranted a comprehensive evaluation of this issue. Active component service members filling a prescription for mefloquine, doxycycline, or atovaquone\/proguanil (A\/P) between January 1, 2008 and June 30, 2013, were included in the analysis. The risk of developing incident NPOs and the risk of subsequent NPOs among subjects with a history of the condition were assessed. A total of 367,840 individuals were evaluated (36,538 received mefloquine, 318,421 received doxycycline, and 12,881 received A\/P). Among deployed individuals prescribed mefloquine, an increased risk of incident anxiety was seen when compared with doxycycline recipients (incidence rate ratio [IRR] = 1.12 [1.01\u20131.24]). Among nondeployed mefloquine recipients, an increased risk of posttraumatic stress disorder (PTSD) was seen when compared with A\/P recipients (IRR = 1.83 [1.07\u20133.14]). An increased risk of tinnitus was seen for both deployed and nondeployed mefloquine recipients compared with A\/P recipients (IRR = 1.81 [1.18\u20132.79]), 1.51 (1.13\u20132.03), respectively). Six percent of the mefloquine cohort had an NPO in the year before receiving mefloquine. When comparing individuals with a prior neuropsychiatric history to those without, the ratio of relative risks for adjustment disorder, anxiety, insomnia, and PTSD were higher (not statistically significant) for mefloquine compared with doxycycline. These findings emphasize the continued need for physicians prescribing mefloquine to conduct contraindication screening.<\/jats:p>","DOI":"10.4269\/ajtmh.16-0390","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T03:30:31Z","timestamp":1479180631000},"page":"159-166","source":"Crossref","is-referenced-by-count":25,"title":["Neuropsychiatric Outcomes After Mefloquine Exposure Among U.S. Military Service Members"],"prefix":"10.4269","volume":"96","author":[{"given":"Angelia A.","family":"Eick-Cost","sequence":"first","affiliation":[{"name":"Epidemiology and Analysis Section, Armed Forces Health Surveillance Branch, Defense Health Agency, Silver Spring, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Hu","sequence":"additional","affiliation":[{"name":"Epidemiology and Analysis Section, Armed Forces Health Surveillance Branch, Defense Health Agency, Silver Spring, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Rohrbeck","sequence":"additional","affiliation":[{"name":"Epidemiology and Analysis Section, Armed Forces Health Surveillance Branch, Defense Health Agency, Silver Spring, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie L.","family":"Clark","sequence":"additional","affiliation":[{"name":"Epidemiology and Analysis Section, Armed Forces Health Surveillance Branch, Defense Health Agency, Silver Spring, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"ref1","series-title":"Clin Infect Dis","first-page":"67","article-title":"Role of US military research programs in the development of US Food and Drug Administration\u2013approved antimalarial drugs","volume":"43","author":"Kitchen","year":"2006"},{"key":"ref2","series-title":"FDA Approves Label Changes for Antimalarial Drug Mefloquine Hydrochloride due to Risk of Serious Psychiatric and Nerve Side Effects","author":"U.S. Food and Drug Administration","year":"2013"},{"key":"ref3","series-title":"Memorandum: Policy Memorandum on the Use of Mefloquine (Lariam) in Malaria Prophylaxis","author":"Office of the Assistant Secretary of Defense (Health Affairs)","year":"2009"},{"key":"ref4","series-title":"Memorandum: Guidance on Medications for Prophylaxis of Malaria","author":"Office of the Assistant Secretary of Defense (Health Affairs)","year":"2013"},{"key":"ref5","series-title":"Am J Trop Med Hyg","first-page":"744","article-title":"Mefloquine use and hospitalizations among US service members, 2002\u20132004","volume":"74","author":"Wells","year":"2006"},{"key":"ref6","series-title":"BMJ","first-page":"1078","article-title":"Tolerability of malaria chemoprophylaxis in non-immune travelers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study","volume":"327","author":"Schlagenhauf","year":"2003"},{"key":"ref7","series-title":"Malar J","first-page":"357","article-title":"The position of mefloquine as a 21st century malaria chemoprophylaxis","volume":"9","author":"Schlagenhauf","year":"2010"},{"key":"ref8","series-title":"Travel Med Infect Dis","first-page":"71","article-title":"Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders","volume":"11","author":"Schneider","year":"2013"},{"key":"ref9","series-title":"Clin Infect Dis","first-page":"1015","article-title":"Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study","volume":"33","author":"Overbosch","year":"2001"},{"key":"ref10","series-title":"J Clin Psychiatry","first-page":"199","article-title":"Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in The Netherlands","volume":"66","author":"van Riemsdijk","year":"2005"},{"key":"ref11","series-title":"Clin Pharmacol Ther","first-page":"294","article-title":"Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events","volume":"72","author":"van Riemsdijk","year":"2002"},{"key":"ref12","series-title":"Cochrane Database Syst Rev","first-page":"CD006491","article-title":"Drugs for preventing malaria in travellers","volume":"4","author":"Jacquerioz","year":"2009"},{"key":"ref13","series-title":"BMJ","first-page":"525","article-title":"Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers","volume":"313","author":"Barrett","year":"1996"},{"key":"ref14","series-title":"Am J Prev Med","first-page":"194","article-title":"Self-reported adverse events associated with antimalarial chemoprophylaxis in peace corps volunteers","volume":"33","author":"Korhonen","year":"2007"},{"key":"ref15","series-title":"J Travel Med","first-page":"226","article-title":"Malaria and mefloquine prophylaxis use among Japan Ground Self-Defense Force personnel deployed in east Timor","volume":"14","author":"Fujii","year":"2007"},{"key":"ref16","series-title":"Drug Healthc Patient Saf","first-page":"87","article-title":"Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malaria","volume":"4","author":"Naing","year":"2012"},{"key":"ref17","series-title":"Am J Trop Med Hyg","first-page":"230","article-title":"Tolerance of mefloquine chemoprophylaxis in Dutch military personnel","volume":"55","author":"Jaspers","year":"1996"},{"key":"ref18","series-title":"Am J Public Health","first-page":"1900","article-title":"The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance","volume":"92","author":"Rubertone","year":"2002"},{"key":"ref19","series-title":"MSMR","first-page":"11","article-title":"Mental disorders and mental health problems, active component, U.S. Armed Forces, 2000\u20132011","volume":"19","author":"Armed Forces Health Surveillance Center (AFHSC)","year":"2012"},{"key":"ref20","series-title":"MSMR","first-page":"12","article-title":"Insomnia, active component, U.S. Armed Forces, January 2000\u2013December 2009","volume":"17","author":"Armed Forces Health Surveillance Center","year":"2010"},{"key":"ref21","series-title":"Case Definitions for Data Analysis and Health Reports: Section 12, Mental Health","author":"Armed Forces Health Surveillance Center","year":"2012"},{"key":"ref22","series-title":"Enhanced Post-Deployment Health Assessment (PDHA) Process (DD Form 2796)","author":"Department of Defense Deployment Health Clinical Center","year":"2006"},{"key":"ref23","series-title":"The Sixth Berkeley Symposium on Mathematical Statistics and Probability","first-page":"737","article-title":"Exact Significance Tests for Contingency Tables Embedded in a 2nd Classification","author":"Zelen","year":"1972"},{"key":"ref24","series-title":"Permutation, Parametric, and Bootstrap Tests of Hypotheses","author":"Good","year":"2005"},{"key":"ref25","series-title":"Stat Sci","first-page":"676","article-title":"Permutation methods: a basis for exact inference","volume":"19","author":"Ernst","year":"2004"},{"key":"ref26","series-title":"Stat Sci","first-page":"189","article-title":"Bootstrap confidence intervals","volume":"11","author":"DiCiccio","year":"1996"},{"key":"ref27","series-title":"Statistical Computing with R","author":"Rizzo","year":"2007"},{"key":"ref28","series-title":"Ann Stat","first-page":"1","article-title":"Bootstrap methods: another look at the jackknife","volume":"7","author":"Efron","year":"1979"},{"key":"ref29","series-title":"Lariam Brand of Mefloquine Hydrochloride Tablets (Package insert)","author":"Roche USA","year":"2004"},{"key":"ref30","series-title":"Med J Aust","first-page":"168","article-title":"Mefloquine and doxycycline malaria prophylaxis in Australian soldiers in east Timor","volume":"182","author":"Kitchener","year":"2005"},{"key":"ref31","series-title":"Eur J Clin Pharmacol","first-page":"441","article-title":"Neuropsychiatric events during prophylactic use of mefloquine before travelling","volume":"58","author":"van Riemsdijk","year":"2002"},{"key":"ref32","series-title":"Travel Med Infect Dis","first-page":"80","article-title":"Acute and long-term psychiatric side effects of mefloquine: a follow-up on Danish adverse event reports","volume":"13","author":"Ringqvist","year":"2014"},{"key":"ref33","series-title":"Case Rep Psychiatry","first-page":"350","article-title":"Severe neuropsychiatric reaction in a deployed military member after prophylactic mefloquine","volume":"2011","author":"Peterson","year":"2011"},{"key":"ref34","series-title":"Br J Clin Pharmacol","first-page":"506","article-title":"Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine","volume":"57","author":"van Riemsdijk","year":"2004"},{"key":"ref35","series-title":"Malar J","first-page":"30","article-title":"Prevalence of contraindications to mefloquine use among USA military personnel deployed to Afghanistan","volume":"7","author":"Nevin","year":"2008"},{"key":"ref36","series-title":"Am J Trop Med Hyg","first-page":"263","article-title":"Pre-travel health, immunization status, and demographics of travel to the developing world for individuals visiting a travel medicine service","volume":"45","author":"Hill","year":"1991"},{"key":"ref37","series-title":"Travel Med Infect Dis","first-page":"718","article-title":"Malaria chemoprophylaxis regimens: a descriptive drug utilization study","volume":"12","author":"Bloechliger","year":"2014"},{"key":"ref38","series-title":"Am J Trop Med Hyg","first-page":"587","article-title":"Compliance with antimalaria chemoprophylaxis in a combat zone","volume":"86","author":"Brisson","year":"2012"},{"key":"ref39","series-title":"MSMR","first-page":"15","article-title":"Surveillance snapshot: self-reported malaria prophylaxis compliance among U.S. service members with diagnosed malaria, 2008\u20132013","volume":"21","author":"Armed Forces Health Surveillance Center","year":"2014"},{"key":"ref40","series-title":"J Travel Med","first-page":"40","article-title":"User acceptability patterns for mefloquine and doxycycline malaria chemoprophylaxis","volume":"3","author":"Phillips","year":"1996"},{"key":"ref41","series-title":"Am J Trop Med Hyg","first-page":"584","article-title":"Safety, tolerability, and compliance with long-term antimalarial chemoprophylaxis in American soldiers in Afghanistan","volume":"93","author":"Saunders","year":"2015"},{"key":"ref42","series-title":"J Infect","first-page":"253","article-title":"The efficacy and tolerability of doxycycline and mefloquine in malaria prophylaxis of the ISAF troops in Afghanistan","volume":"51","author":"Sonmez","year":"2005"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/96\/1\/article-p159.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/96\/1\/article-p159.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/96\/1\/article-p159.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T22:45:02Z","timestamp":1723070702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/96\/1\/article-p159.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":42,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.16-0390","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]}}}